Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04072263
Other study ID # OVACURE
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date August 1, 2018
Est. completion date December 1, 2021

Study information

Verified date March 2021
Source Leiden University Medical Center
Contact Judith Kroep, MD, PhD
Phone 0031715263464
Email j.r.kroep@lumc.nl
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The clinical benefit of standard treatment for patients with epithelial ovarian cancer (EOC) are poor. Ovarian cancer is a highly immunogenic tumor and good survival is tightly linked to the presence of tumor-infiltrating CD8+ T cells and the absence of immunosuppressive immune cells. This clear correlation between T cell infiltration and disease progression suggests that EOC may be sensitive to adoptive cell therapy by infusion of ex-vivo expanded autologous Tumor Infiltrating Lymphocytes (TIL) provided that immune suppression is reduced. Carboplatin+paclitaxel chemotherapy is directly killing tumor cells but was also shown to alleviate immunosuppression for 2 weeks coinciding with enhanced T-cell immunity, potentially creating a window of opportunity for T-cell based immunotherapy. In addition, there is evidence that interferon alpha (IFNα) not only may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells. Based on this we hypothesize that a synergistic clinical effect may be obtained when adoptive cell therapy with autologous TIL is administered during treatment with chemotherapy and IFNα. The feasibility and safety of TIL administration is studied in the window of opportunity created by carboplatin-paclitaxel chemotherapy with or without interferon alpha (IFNα). Furthermore, exploratory studies will be performed to analyze and confirm the proposed underlying mechanisms. Tumor material for TIL production will be collected during first line debulking surgery in case of FIGO stage IIIC/IV disease (pre-OVACURE) or in case of recurrent platinum sensitive disease an extra biopsy can be planned (OVACURE).


Description:

Study the feasibility and safety of TIL administration in the window of opportunity created by carboplatin-paclitaxel chemotherapy with or without interferon alpha (IFNα). Furthermore, exploratory studies will be performed to analyze and confirm the proposed underlying mechanisms. Intervention: Cohort 1 - Carboplatin-paclitaxel day1, q3 weeks, 6x, plus - TIL starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x. Cohort 2 - Carboplatin-paclitaxel day1, q3 weeks, 6x, plus - TIL starting 14 days after the 2nd chemotherapy cycle, q3 weeks, 3x, plus - IFNα (3x10e6 U daily) starting one week before the first TIL infusion for 12 weeks in total.


Recruitment information / eligibility

Status Recruiting
Enrollment 12
Est. completion date December 1, 2021
Est. primary completion date August 1, 2021
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years. - Histologically proven epithelial ovarian cancer (EOC). - Recurrent ovarian cancer amenable to carboplatin and paclitaxel chemotherapy. Patient with primary stage III or IV EOC can participate in the pre-OVACURE to collect rest tumor during debulking surgery for TILs preservation, so TILs will be available in case of recurrent disease will develop in the future. - Presence of measurable progressive disease according to RECIST version 1.1 or elevated CA125 = 2 times the upper normal limit (UNL) within 3 months and confirmed. - Expected survival of at least 3 months. - WHO performance status 0-2. - Within the last 2 weeks prior to study day 0, vital laboratory parameters should be within normal range, except for the following laboratory parameters, which should be within the ranges specified: Lab Parameter Range Hemoglobin = 6,0 mmol/l Granulocytes = 1,500/µl Lymphocytes = 700/µl Platelets = 100,000/µl Creatinine clearance = 50 min/ml Serum bilirubin = 40 mol/l ASAT and ALAT = 5 times the normal upper limit LDH = 2 times the normal upper limit - Viral tests: - Negative for HIV type 1/2, HTLV and TPHA - No HBV (hepatitis B virus) antigen or antibodies against HBc in the serum - No antibodies against HCV (hepatitis C virus) in the serum - Able and willing to give valid written informed consent. - Prior treatment, including immunotherapy e.g. with anti-PD(L)1, is allowed but systemic therapy and radiotherapy must have been discontinued for at least two weeks before study entry. - Patients should have disease progression. Exclusion Criteria: - Patients with brain metastases. - Clinically significant heart disease (NYHA Class III or IV). - Other serious acute or chronic illnesses, e.g. active infections requiring antibiotics, bleeding disorders, or other conditions requiring concurrent medications not allowed during this study. - Active immunodeficiency disease or autoimmune disease requiring immune suppressive drugs. Vitiligo is not an exclusion criterion. - Other malignancy within 2 years prior to entry into the study, except for treated non-melanoma skin cancer and in situ cervical or vulva carcinoma. - Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study. - Lack of availability for follow-up assessments. - Pregnancy or breastfeeding.

Study Design


Intervention

Biological:
Tumor Infiltrating Lymphocytes (TIL)
Adoptive cell therapy using Tumor-Infiltrating Lymphocytes (TIL) i.v.
Drug:
Interferon Alfa 2A
Interferon alpha (IFNa) s.c., may work as a low toxic preconditioning regimens that creates the space required for the infused TIL but that it also supports the TIL by sustaining their persistence and indirectly their function, by upregulation of HLA class I on tumor cells and decreasing the numbers of regulatory T cells.
Carboplatin
chemotherapy i.v.
Paclitaxel
Chemotherapy i.v.

Locations

Country Name City State
Netherlands Leiden University Medical Center Leiden ZH

Sponsors (1)

Lead Sponsor Collaborator
Leiden University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary NCI CTC criteria If a DLT occurs in more than one out of the three patients, the study will be stopped. If < 1 out of 3 patients have a DLT, then three additional patients will be treated. Therefore, a minimum of 3 and a maximum of 6 patients will be treated in both cohorts. 3 years
Secondary Clinical Response Clinical response according to RECIST 1.1 criteria and immune response criteria (irRC) 3 years
Secondary Disease Control rate Disease control rate (DCR: CR+PR+SD) at 6 months 3 years
Secondary Progression free survival (PFS) Progression free survival (PFS) is defined as: the duration from the time of start chemotherapy until first observation of radiologically confirmed progressive disease or death due to any cause, whichever occurred first. 3 years
Secondary Overall Survival (OS) Overall Survival (OS) is defined as: the duration from the time of start of chemotherapy until death from any cause. 3 years
See also
  Status Clinical Trial Phase
Recruiting NCT06014528 - IN10018 in Combination With Pegylated Liposomal Doxorubicin (PLD) vs. Placebo in Combination With PLD for the Treatment of Platinum-resistant Recurrent Ovarian Cancer Phase 2
Recruiting NCT05001282 - A Study to Evaluate ELU001 in Patients With Solid Tumors That Overexpress Folate Receptor Alpha (FRα) Phase 1/Phase 2
Recruiting NCT03717610 - Hyperthermic Intraperitoneal Chemotherapy for Treatment of Relapsed Ovarian Cancer N/A
Active, not recruiting NCT04175470 - Bevacizumab and Tocotrienol in Recurrent Ovarian Cancer Phase 2
Recruiting NCT03983226 - Surgery and Niraparib in Secondary Recurrent Ovarian Cancer (SOC-3 Trial) Phase 2
Recruiting NCT05095558 - Microtransplantation for Ovarian Cancer Phase 1/Phase 2
Completed NCT03657966 - DCVAC/OvCa After Standard-of-care Chemotherapy in Women With Relapse of Platinum-sensitive Epithelial Ovarian Cancer Phase 2
Not yet recruiting NCT06102707 - The Efficacy and Safety of Fluzopril Combined With Apatinib in Maintenance Treatment of Platinum Resistant Recurrent Ovarian Cancer Patients N/A
Terminated NCT03162562 - The Safety and Antitumor Activity of the Combination of Oregovomab and Hiltonol in Recurrent Advanced Ovarian Cancer Phase 1
Withdrawn NCT04149145 - Trial of M4344 and Niraparib in Patients With Poly (ADP-ribose) Polymerase (PARP) Resistant Recurrent Ovarian Cancer Phase 1
Completed NCT01332656 - Study of Ombrabulin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer Treated With Carboplatin/Paclitaxel Phase 2
Completed NCT01111903 - A 2 Stage Trial of Lenalidomide (REV) in Asymptomatic Ovarian Cancer Patients With Increasing CA 125 in Late Relapse Phase 1/Phase 2
Recruiting NCT03734692 - Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer Phase 1/Phase 2
Recruiting NCT03827837 - Famitinib Plus Anti-PD1 Therapy for Advanced Urinary System Tumor, Advanced Gynecological Tumors Phase 2
Not yet recruiting NCT05990192 - SBRT Alone or Followed by Niraparib for Oligometastases or Oligoprogression in Ovarian Cancer Following PARPi Therapy Phase 2
Completed NCT01485848 - EP-100 Plus Paclitaxel Versus Paclitaxel Alone in Patients With Ovarian Cancer Phase 2
Completed NCT03681548 - A Study of Doxorubicin Hydrochloride Liposome Injection in Subjects With Ovarian Cancer. Phase 1